Pharmacokinetics of Repeated Oral Doses of Amlodipine and Amlodipine plus Telmisartan in Healthy Volunteers

氨氯地平 生物等效性 替米沙坦 药代动力学 最大值 交叉研究 医学 药理学 安慰剂 内科学 血压 病理 替代医学
作者
Joachim Stangier,Chung‐An P. F. Su
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
卷期号:40 (12): 1347-1354 被引量:25
标识
DOI:10.1177/009127000004001206
摘要

This open‐label, crossover study was performed to establish if there is evidence for interaction between telmisartan, an angiotensin II antagonist, and amlodipine, a class II (dihydropyridine) calcium channel antagonist, on the basis of pharmacokinetics and safety. In a two‐way crossover trial, 12 healthy Caucasian males were randomized to receive once daily for 9 days oral amlodipine 10 mg with or without oral telmisartan 120 mg. After a washout period of ≥ 13 days, the subjects were switched to the other medication regimen. The geometric means of the primary pharmacokinetic parameters at steady state (day 9) for amlodipine when given alone were the following: maximum plasma concentration (C max ) 17.7 ng/mL, area under the plasma concentration‐time curve (AUC) 331 ng•h/mL, and renal clearance 39.5 mL/min, with 8% of the total amlodipine dose being excreted. When concomitant telmisartan was given, the respective values were 18.7 ng/mL, 352 ng•h/mL, and 43.0 mL/min, with 9.4% of the total amlodipine dose being excreted renally The limits of the 90% confidence intervals (CIs) for the ratios of these steady‐state parameters were 0.97 to 1.14 for C max and 0.98 to 1.16 for AUC; both were within the predefined reference range (0.8 to 1.25) for bioequivalence. The high intersubject variability in urinary amlodipine excretion resulted in bioequivalence not being demonstrated for renal clearance. Adverse effects were few, mild to moderate in intensity, and transient whether amlodipine was given alone or with telmisartan. Vital signs, except for blood pressure, and clinical laboratory values were unaffected by either medication. The findings of this study show that concomitant telmisartan and amlodipine may be administered as there is no clinically significant variation in primary pharmacokinetic parameters of amlodipine in the presence of telmisartan, and the safety of the combination is comparable to that of amlodipine alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sunshine发布了新的文献求助10
刚刚
福生完成签到,获得积分10
刚刚
快到碗里来完成签到 ,获得积分10
刚刚
1秒前
2秒前
2秒前
2秒前
生动煎饼发布了新的文献求助10
2秒前
3秒前
王诗琪发布了新的文献求助60
3秒前
4秒前
冯新完成签到,获得积分20
4秒前
scloar发布了新的文献求助10
4秒前
小蘑菇的应助被憨憨采纳,获得10
4秒前
5秒前
5秒前
向阳发布了新的文献求助10
5秒前
lili发布了新的文献求助10
5秒前
5秒前
北方的艳阳完成签到,获得积分10
6秒前
imss1发布了新的文献求助10
7秒前
yaoenhao发布了新的文献求助10
8秒前
苹果怀莲的应助被功率看到采纳,获得10
9秒前
CC完成签到 ,获得积分10
9秒前
9秒前
星辰大海的应助被安好采纳,获得10
9秒前
科研通AI6.2的应助被ss采纳,获得10
10秒前
RON发布了新的文献求助10
11秒前
GEN发布了新的文献求助10
11秒前
11秒前
CodeCraft的应助被Roxxane采纳,获得10
12秒前
Yvonne完成签到,获得积分10
13秒前
粥vbbb完成签到 ,获得积分10
13秒前
化学民工发布了新的文献求助10
13秒前
13秒前
酷波er的应助被筱南竹折采纳,获得10
14秒前
14秒前
Lynn完成签到 ,获得积分10
14秒前
Akim的应助被dart1023采纳,获得10
15秒前
Siri完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)通过应助OA文献获取积分 10000
Rosenblum, Global Change Biology 800
A Silent Apostrophe:The Fayum Portraits 520
Organizational Behavior 510
Sing with Understanding: Introduction to Theology in Christian Congregational Song, 3rd ed 330
Auslegung und Untersuchung einer invers ausgelegten Beschaufelung eines einstufigen Axialverdichters mit Vorleitrad (German) 300
AI-Contracting 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 有机化学 化学工程 内科学 物理 生物化学 复合材料 催化作用 细胞生物学 人工智能 心理学 无机化学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 7838215
求助须知:如何正确求助?哪些是违规求助? 9360564
关于积分的说明 20615795
捐赠科研通 7432221
什么是DOI,文献DOI怎么找? 3339047
关于科研通互助平台的介绍 2483359
邀请新用户注册赠送积分活动 2360018